Sort
51,593 grants matching “hepatitis”
Role of Wnt/beta-catenin In Liver Regeneration
$428,699Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · DK
Metabolic and xenobiotic control of thyroid hormone metabolism
$428,667Antonio C Bianco · University Of Chicago · R01 · FY2024 · DK
Computational Approaches for RNA StructureFunction Determination
$428,638Bruce Shapiro · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
ENaC regulation by biliary factors
$428,594Ossama B Kashlan · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · DK
Cellular Roles in Liver Pathology: Dioxin as Prototype
$428,593Christopher A Bradfield · University Of Wisconsin-Madison · R01 · FY2008 · ES
Phase I Clinical Trials of Novel Anticancer Agents
$428,589Merrill J Egorin · University Of Pittsburgh At Pittsburgh · U01 · FY2007 · CA
Lopinavir/ritonavir + zidovudine to prevent perinatal HIV in Thailand
$428,547Marc J Lallemant · Harvard School Of Public Health · R01 · FY2007 · HD
Reducing Hazardous Alcohol Use & HIV Viral Load:An RCT in ART Clinics in Vietnam
$428,537Vivian F. Go · Univ Of North Carolina Chapel Hill · R01 · FY2017 · DA
Phase I Clinical Trials of Novel Anticancer Agents
$428,535Chandra Belani · University Of Pittsburgh At Pittsburgh · U01 · FY2006 · CA
Exercise and Fuel Metabolism
$428,508David H Wasserman · Vanderbilt University · R37 · FY2014 · DK
Exercise and Fuel Metabolism
$428,508David H Wasserman · Vanderbilt University · R37 · FY2015 · DK
Exercise and Fuel Metabolism
$428,508David H Wasserman · Vanderbilt University · R37 · FY2017 · DK
Exercise and Fuel Metabolism
$428,508David H Wasserman · Vanderbilt University · R37 · FY2016 · DK
Effects of Niacin on Lp(a), Oxidized LDL, and inflammation in the AIM-HIGH trial
$428,498Daniel James Rader · University Of Pennsylvania · R01 · FY2012 · HL
Molecular Modulation of Virus Capsid Assembly
$428,479Adam Zlotnick · Trustees Of Indiana University · R01 · FY2015 · AI
Targeting the mitochondrial pyruvate carrier to treat insulin resistance and nonalcoholic fatty liver disease
$428,476Brian N Finck · Washington University · R01 · FY2021 · DK
Targeting the mitochondrial pyruvate carrier to treat insulin resistance and nonalcoholic fatty liver disease
$428,476Brian N Finck · Washington University · R01 · FY2022 · DK
Targeting the mitochondrial pyruvate carrier to treat insulin resistance and nonalcoholic fatty liver disease
$428,476Brian N Finck · Washington University · R01 · FY2023 · DK
Role of PDZK1 in lipid metabolism and atherosclerosis
$428,475Olivier N. Kocher · Beth Israel Deaconess Medical Center · R01 · FY2015 · HL
Environmental chemical exposures during pregnancy and women's cardio-metabolic health
$428,440Dana Dabelea · University Of Colorado Denver · R01 · FY2022 · ES
Hepatic mTORC1 Signaling and the Regulation of Lipid Homeostasis
$428,417Paul Michael Titchenell · University Of Pennsylvania · R01 · FY2022 · DK
The Role of HMGB1 in autophagy deficiency-induced liver pathology
$428,405Xiao-Ming Yin · Indiana University Indianapolis · R01 · FY2018 · DK
Re-engineering a human 3D liver tissue model for non-alcoholic fatty liver disease for drug screening
$428,360Mark T. Miedel · University Of Pittsburgh At Pittsburgh · UH2 · FY2023 · TR
Disulfiram Interactions With HIV Medications: Clinical Implications
$428,339Elinore F. McCance-Katz · University Of California, San Francisco · R01 · FY2010 · DA
Mechanisms of Liver Toxicity of Anit-Depressant Duloxetine
$428,322Feng Li · Baylor College Of Medicine · R01 · FY2022 · DK